<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03810573</url>
  </required_header>
  <id_info>
    <org_study_id>NB1-100</org_study_id>
    <nct_id>NCT03810573</nct_id>
  </id_info>
  <brief_title>Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis</brief_title>
  <official_title>A Multi-Center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety And Preliminary Effectiveness Of NB1 Bone Graft In Subjects With Degenerative Disc Disease Undergoing Transforaminal Lumbar Interbody Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bone Biologics Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bone Biologics Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the safety and effectiveness of NB1 Bone
      Graft in subjects with degenerative disc disease undergoing transforaminal lumbar interbody
      fusion.

      It is estimated that up to 30 participants will be enrolled in approximately 3 clinical
      sites. During baseline and follow-up assessments, patients will be asked to undergo x-rays
      and CT scans; adverse events and immunology will be collected, and; participants will be
      requested to complete participant questionnaires regarding quality of life, pain and
      function.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion</measure>
    <time_frame>12 months</time_frame>
    <description>Defined by an independent (blinded to treatment) radiological assessment as less than five degrees angular vertebral motion, less than three millimeters of translational movement and evidence of bridging bone between the involved vertebral endplates based on x-rays at 12 months after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Removal, revision, or supplemental fixation</measure>
    <time_frame>12 months</time_frame>
    <description>Whether there was removal, revision or supplemental fixation of the graft material that required reoperation at the index level during the follow-up period of the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Spondylolisthesis</condition>
  <arm_group>
    <arm_group_label>NB1-1.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NB1 low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NB1-2.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NB1 high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autograft</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Autograft</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NB1</intervention_name>
    <description>rhNELL-1/DBX</description>
    <arm_group_label>NB1-1.5</arm_group_label>
    <arm_group_label>NB1-2.0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of degenerative disc disease

          -  Up to Grade I spondylolisthesis

          -  Eligible to undergo a single vertebral level spine fusion (L2 to S1)

        Exclusion Criteria:

          -  Previous spinal instrumentation or previous interbody fusion procedure at the involved
             level

          -  Grade II or greater spondylolisthesis

          -  Systemic or local infection at the site of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Goldschlager, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brent Atkinson, PhD</last_name>
    <phone>13035507866</phone>
    <email>atkinsonbrent520@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Tony Goldschlager, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tony Goldschlager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>As requested</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

